The Best Quarter Since 2015 Meets a 19x Multiple and a $1.5B Biktarvy Price Cut: Downgrading to Hold

Results vs. Consensus

Q3 2026 Scorecard

Year-Over-Year Comparisons

Quarter-Over-Quarter Comparisons

Quality of Beat

Revenue: Strong, but about half of the surprise may reverse. Total revenues beat consensus by roughly $480M–$510M, and the miss on royalty income makes the headline 7% growth understate the operating result. Product sales grew 13% and the base business 16%. The caveat is composition. Gilead's own filing attributes HIV growth to "higher average realized price, higher demand in HIV prevention and favorable inventory dynamics," and Descovy's 49% primarily to price and inventory. One Street estimate puts roughly half of the revenue beat in inventory. Geography makes the same point from a different angle: U.S. product sales grew 21%, while Europe fell 8% and the rest of the world fell 6%, mostly on Veklury and cell therapy. Gilead's growth this quarter was American, which is also where the 2028 price cut lands.

Margins: Better than the table shows. Non-GAAP product gross margin rose to 88.1% on the expiry of a tenofovir alafenamide royalty obligation in November 2025, a structural benefit that begins to lap in the fourth quarter. Non-GAAP operating margin of 50.2% looks flat against 50.5%, but the year-ago figure carried about $400M of near-pure-margin royalty revenue. Remove it and the underlying margin rose from roughly 47.8% to 50.2%. The pressure is in operating expense: non-GAAP R&D grew 19% and SG&A 14%, which management attributed to bonus accruals tied to the year's outperformance, HIV promotion and legal costs.

EPS: Operational, against a tax and royalty headwind. The non-GAAP tax rate rose to 19.0% from 17.5%, the diluted share count was flat at 1,251M, and other income contributed less than a year ago. None of those flattered the result. GAAP EPS fell 20% to $1.94, but the gap is a $164M loss on equity securities this year against a $483M gain last year, and that line sits outside operations.

Segment Performance

Product Mix: Q3 2026

Geographic Mix: Q3 2026

The geographic split is the less-discussed half of the quarter. All of the HIV acceleration came from the United States, where realized price, channel mix and wholesaler stocking all operate. European HIV sales were flat. Outside the U.S., total product sales declined on Veklury's collapse and the Kite erosion, which hit Europe hardest (European cell therapy fell to $138M from $186M). The growth story is real, but it is concentrated in the one market where the company has just been told its largest product will be repriced.

HIV treatment: Biktarvy at a record share, Bixlenvo off the line

Biktarvy grew 10% to $4,059M, with U.S. sales up 12%, and reached a 53% U.S. treatment share, its highest ever. The filing credits demand, including patients switching from Genvoya and other Gilead regimens, then price, then inventory. Sequentially the product grew 8% on stocking and demand, partly offset by lower realized price from channel mix. Bixlenvo, the once-daily bictegravir plus lenacapavir tablet approved in August, made what management called a modest initial contribution after a late-August launch.

"While we have not yet seen the HIV treatment market return to its typical 2% to 3% growth, we have seen signs of stabilization." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

That sentence answers one of our open questions from August, and the answer is "not yet." Biktarvy is taking share in a market that is still growing below its normal rate, which makes the record share more impressive and the market-level recovery still an assertion.

Assessment: Share gains at 53% in a soft market are the best evidence of Biktarvy's competitive position we have seen. They also mean more of the franchise's growth now comes from taking patients than from a growing pool, and share has a ceiling that market growth does not.

Prevention: Yeztugo leads the injectables, Descovy carries the dollars

HIV prevention sales nearly doubled year over year against a U.S. PrEP market growing 14%. Yeztugo reached $305M, up 31% sequentially, and management said it is now the leading injectable prevention regimen. The six-month return rate for the second injection held above 70%. Descovy, about 80% PrEP, grew 49% to $1,046M and has already passed its full-year 2025 sales in three quarters.

"Importantly, we continue to see that more than 70% of users have returned for their second injection, resulting in combined protection of up to a full year." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

The full-year Yeztugo guide of approximately $1B was held, not raised. With $702M booked through September, that implies a fourth quarter near $298M, roughly flat on Q3. Management framed this as holiday seasonality.

Assessment: Yeztugo delivered the roughly $300M-a-quarter run rate we said in August it needed to reach the guide, and persistency held. The unchanged guide is conservative rather than cautionary. The larger dollar story remains Descovy, whose growth this quarter came from price and stocking more than demand by the company's own account.

Liver disease: Livdelzi nearly doubles

Liver disease sales grew 13% to $927M. Livdelzi rose 93% to $203M and 22% sequentially, with growth in both the U.S. and Europe. Vemlidy grew 19% on hepatitis B pricing, while sofosbuvir/velpatasvir fell 11% on fewer hepatitis C starts. Detailed Phase 3 IDEAL results go to the AASLD meeting, and management expects a U.S. label update in 2027.

"Livdelzi is the market leader in the U.S., and is helping to drive expansion of the second-line PBC market." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Livdelzi is annualizing above $800M and still compounding at more than 20% a quarter. The IDEAL population, patients with alkaline phosphatase between 1 and 1.67 times the upper limit of normal, is roughly half of the second-line eligible pool, so the 2027 label is a genuine expansion rather than a line extension.

Trodelvy: a $2B run rate and the first-line franchise forming

Trodelvy grew 42% to $506M and 11% sequentially on demand in both metastatic triple-negative and HR-positive/HER2-negative breast cancer. The European Commission approved the pembrolizumab combination in first-line PD-L1-positive metastatic TNBC, completing first-line coverage across PD-L1 status in both the U.S. and Europe. A new collaboration with BioNTech will test Trodelvy with pumitamig, a PD-L1/VEGF-A bispecific, in first-line TNBC.

"Following the first-line approvals in the U.S. and Europe earlier this year, Trodelvy is establishing itself as the backbone of treatment in metastatic triple-negative breast cancer, and we're working to expand Trodelvy's first-line opportunity further into new markets." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Last quarter we wrote that diversification was real in the pipeline but not yet in dollars, because Kite consumed Trodelvy's growth and oncology grew 3%. This quarter oncology grew 9%, the first time this year Trodelvy has visibly outrun the cell therapy decline. The ASCENT-GYN endometrial readout, due around year-end, is the next test of whether the asset extends beyond breast cancer after the lung write-off.

Cell therapy: still shrinking, with the launch ten weeks out

Cell therapy sales fell 18% to $355M and 15% sequentially, with Yescarta down 16% and Tecartus down 28% on competition. The full-year mid-teens decline guide was held, and the year-to-date decline is 15%. The December 23 PDUFA date for anito-cel in fourth-line-plus multiple myeloma is the offset, and management gave concrete launch targets for the first time.

"Coupling our steadfast preparations with the level of health care provider and patient enthusiasm we have seen for anito-cel's profile ahead of launch, we are targeting brand leadership in the fourth line plus setting within 18 months of approval." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Against that, PALISADES-1 and 2, the trials of next-generation KITE-753 in second- and third-line-plus diffuse large B-cell lymphoma, went on partial clinical hold over higher-grade neurotoxicity in a small number of patients.

Assessment: The decline is tracking the guide rather than worsening, which is an improvement on last quarter's unexplained cut. Brand leadership within 18 months is a specific, gradeable commitment. The KITE-753 hold does not touch anito-cel, but it narrows Kite's next-generation lymphoma bench at the moment the legacy products are eroding fastest.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Management was the most confident it has been all year, and with reason, leading with the strongest base-business growth since 2015 and a third consecutive guide raise. The one defensive passage was the Biktarvy price, where the company paired an unusually detailed 2028 disclosure with a firm commitment to growth and a pointed objection to the policy. Where management was less forthcoming was on the quality of the quarter: the inventory build was acknowledged but never sized, and the split of the $1.5B impact was declined.

1. The fastest base-business growth since 2015

Base-business sales grew 16% to $8,203M, and HIV grew 18%, its fastest year-over-year rate since the fourth quarter of 2018. Five products did the work: Biktarvy, Descovy and Yeztugo in HIV, Trodelvy in breast cancer and Livdelzi in PBC. The base business is now guided to $30.7B–$31.0B for the year, which is $1.65B above the February midpoint after three raises.

"Third quarter base business sales were up 16% year-over-year, Gilead's strongest growth in more than a decade, driven by Biktarvy, Descovy and Yeztugo in HIV, Trodelvy in metastatic breast cancer, and Livdelzi in PBC." — Daniel O'Day, Chairman & CEO

The year-to-date base business grew 11%, a better measure than the single quarter because it nets out the timing of channel purchases. That is still roughly double the 4%–5% growth framed at the start of the year.

Assessment: Whatever share of Q3 proves to be timing, an 11% year-to-date base-business growth rate for a company of this size, with five growth products contributing, settles the debate about whether Gilead is a maturity story. It is not.

2. The inventory question: how much of Q3 belongs to Q4

Management was candid that the quarter benefited from stocking, and equally careful not to size it. HIV's 10% sequential growth was attributed first to higher inventory, and the CFO guided the fourth-quarter build below its usual seasonal level as a direct consequence.

"Sequentially, HIV sales were up 10%, primarily driven by higher inventory, demand and average realized price. We expect these inventory dynamics to normalize by year-end." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

"Given larger inventory build than is typical for the third quarter, we expect the Q4 inventory build to be smaller than we have historically seen in the fourth quarter." — Andrew Dickinson, Chief Financial Officer

The full-year guide makes the effect visible. Roughly 12% HIV growth on 2025's $20,752M implies about $6,270M in the fourth quarter, essentially flat on Q3 and about 8% above the $5,801M of Q4 2025. In other words, the guide already assumes HIV growth halves in the fourth quarter.

Assessment: This is the most important quality caveat of the quarter, and management handled it honestly in direction if not in magnitude. We treat Q3's 18% as roughly 12% to 13% of underlying growth plus a timing benefit that reverses in Q4. That is still excellent, but it is not 18%, and the stock is now priced closer to the headline than to the underlying rate.

3. The ACA hit finally has a size

In August we flagged that management called the Affordable Care Act subsidy expiry "greater-than-expected" without quantifying it. This quarter the CFO sized the year's policy headwind as part of a broader argument that Gilead absorbs policy shocks.

"Taking a step back, Gilead has demonstrated its ability to address policy impacts over the last few years, including the $1.1 billion headwind associated with Medicare Part D redesign in 2025, and the greater than $500 million headwind associated with the Affordable Care Act and other government policies in 2026." — Andrew Dickinson, Chief Financial Officer

Assessment: More than $500M is roughly 2.4% of 2025 HIV sales, consistent with the two-point drag management framed in February, and the business raised its HIV growth guide twice while absorbing it. The number answers our question. The fact that it was offered as context for the Biktarvy price, rather than in its own right, tells you what management wanted investors to take from it.

4. Biktarvy's Maximum Fair Price: $2,600 a month, about $1.5B in 2028

The quarter's most consequential disclosure was not about the quarter. CMS completed the Inflation Reduction Act price-setting process for Biktarvy, and Gilead gave an unusually specific estimate of the effect two years before it starts.

"More specifically, we expect a total net impact to Biktarvy revenue of approximately $1.5 billion in 2028, reflecting the lower price in Medicare, in addition to related impacts across other U.S. channels, including Medicaid, 340B and other payer segments." — Andrew Dickinson, Chief Financial Officer

The price is $2,600 per 30-day supply, about 38% below list in the Medicare channel, effective January 1, 2028. Management expects 2028 Biktarvy revenue to decline from 2027. The $1.5B is net of the Part D redesign effect that rolls off in 2028, and it equals about 10.5% of 2025 Biktarvy sales and about 5% of this year's product-sales guide. The chief executive used the Q&A to object to the outcome directly.

"First, I'd just like to say that the price set by CMS does not reflect the value of Biktarvy, the medicine that has transformed HIV treatment and widely recognized as a standard of care." — Daniel O'Day, Chairman & CEO

Assessment: This converts the policy bear point from a risk into a dated, sized liability. The number is large but not thesis-breaking, and the disclosure deserves credit: guiding a 2028 effect in October 2026 is more than most companies offer. But the largest product in the company now has a known step-down, and any valuation that treats Gilead's HIV annuity as running untouched to 2036 needs to be revised.

5. The 2028 commitment: growth through the price cut

Management paired the bad news with a commitment that will define how the stock trades for the next two years.

"Reflecting growth from other innovations across our HIV portfolio, we continue to expect total HIV revenue to grow in 2028 compared to 2027." — Andrew Dickinson, Chief Financial Officer

"As a result, we expect both total product sales and earnings per share to grow in 2028 compared to 2027." — Andrew Dickinson, Chief Financial Officer

The growth has to come from the long-acting portfolio: Yeztugo, a once-weekly oral PrEP decision in early February 2027, once-yearly lenacapavir targeted for 2028, Bixlenvo, and islatravir plus lenacapavir with a filing this year and a decision in 2027. Asked how the $1.5B gets offset, management said it has about a year to mitigate and offered no breakdown.

Assessment: This is the most important forward commitment Gilead has made since we initiated, and it is gradeable. Growing HIV revenue through a $1.5B reduction in its largest product requires the prevention franchise and the new regimens to add more than $1.5B in a single year on top of normal erosion. We think that is achievable on the current trajectory. It is also the reason we do not move to Underperform: the company has bounded the downside it just disclosed.

6. Revenue finally converts to earnings

In August a $350M base-business raise moved illustrative EPS by five cents at the bottom and nothing at the top, and we held conviction at 7 because of it. This quarter the conversion worked.

"Excluding approximately $9.95 per share related to the acquired IPR&D expense and full year financing costs associated with the acquisitions this year and nonrecurring other revenue, our full year non-GAAP diluted EPS would be $8.75 to $9.10, raised $0.25 on both ends from our illustrative August guidance due to higher base sales, partially offset by higher operating expenses." — Andrew Dickinson, Chief Financial Officer

The guidance table shows it more cleanly. Non-GAAP operating income guidance fell to $2.0B–$2.4B only because acquired IPR&D rose by $1.4B. Add the IPR&D back and operating income excluding it moved from $14.4B–$14.8B to $14.9B–$15.3B, up $500M on a $900M revenue raise. The offset is operating expense: R&D is now guided up a mid-to-high single-digit percentage and SG&A up a high single-digit percentage, both from mid-single-digit, which management tied to bonus accruals on the outperformance.

Assessment: Our fifth bear point is answered. About 55% incremental conversion on the revenue raise is what a business at a 50% operating margin should deliver. The expense creep is real, but a bonus accrual tied to a beat is the right kind of cost growth, and it should not compound into 2027 the way a structural headcount build would.

7. Prevention: weekly oral next, yearly after

Gilead holds 50% of the PrEP market with Yeztugo and Descovy for PrEP, at a $4B annual run rate. The pipeline behind it is designed to cover every dosing preference: once-weekly oral lenacapavir is under FDA review with a decision expected in early February 2027, and the PURPOSE-365 Phase 3 of once-yearly intramuscular lenacapavir reports in 2027, with launch targeted for 2028.

"Looking ahead, we believe the potential launch of once-weekly oral Yeztugo could further expand choice and support continued growth by reaching additional individuals who could benefit from PrEP." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

The weekly oral will launch into the access Yeztugo has already won, about 70% of the pharmacy-benefit space, which management expects to support a faster ramp than a new brand would see.

Assessment: The weekly oral is the most important near-term product for the 2028 commitment, because, as management said in August, 80% to 85% of the PrEP market still takes a daily pill and a weekly pill can convert generic Truvada users at branded prices. The February 2027 decision is now the nearest major catalyst in the name.

8. HIV treatment: Bixlenvo launched, the long-acting bench widens, and a clinical hold

Bixlenvo was approved and launched in August for virally suppressed adults, including patients switching off complex multi-tablet regimens. Behind it, Gilead has six long-acting treatment programs. Islatravir plus lenacapavir, a once-weekly oral partnered with Merck, will be filed this year. Phase 2 trials combining lenacapavir with the in-house integrase inhibitors are under way for GS-3242 and start in early 2027 for GS-1720, and the Phase 3 DAYBREAK trials of lenacapavir plus two broadly neutralizing antibodies began in the quarter.

"We expect to file islatravir plus lenacapavir with FDA this year with a regulatory decision in 2027." — Dietmar Berger, Chief Medical Officer

One program moved the other way. GS-3107, a monthly oral prodrug, is on clinical hold after unexpected metabolite effects, and management is advancing backup molecules for the monthly slot.

Assessment: Bixlenvo addresses the switch leak we identified in August, and the weekly and twice-yearly programs give Gilead a credible answer to every competing dosing schedule. The GS-3107 hold delays the monthly oral rather than closing it, and the monthly slot was never central to the 2028 bridge.

9. Trodelvy and the oncology bench

With Trodelvy at an annual run rate of about $2B, the oncology question has shifted from whether the asset works to how far it extends. Beyond breast cancer, the ASCENT-GYN endometrial cancer Phase 3 update is due around year-end. The Tubulis acquisition added four clinical-stage programs, and the oncology ADC count now stands at seven, including GS-8824, the NaPi2b-directed ADC in platinum-resistant ovarian cancer.

"Among our ADC programs, we look forward to providing an update from our Phase III ASCENT-GYN study around the end of the year." — Dietmar Berger, Chief Medical Officer

Assessment: Oncology is now contributing visible growth for the first time this year. ASCENT-GYN is the first late-stage Trodelvy readout outside breast cancer since EVOKE-03 failed, so its result matters for how the market values the franchise beyond 2028.

10. Anito-cel: a launch plan with numbers on it

Kite gave its most concrete launch framework yet for anito-cel ahead of the December 23 PDUFA date: 80% of authorized treatment centers activated within six months, 90% payer coverage within twelve months, and brand leadership in the fourth-line-plus setting within eighteen months. Newly diagnosed studies, iMMagine-4 and iMMagine-6, start in early 2027, and iMMagine-3 in second- to fourth-line could support a filing as early as 2027.

"This includes: conducting preactivation efforts within our Authorized Treatment Centers network, with a target activation of 80% of our ATCs within the first 6 months of launch, detailed launch planning across sales, medical and access teams as well as engaging with a range of payers with a target of 90% payer coverage within the first 12 months of launch." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Specific launch metrics are exactly what investors need to grade Kite's turnaround through 2027, and we will carry them as commitments. Anito-cel contributes nothing to 2026 and little to the first half of 2027, so the cell therapy line keeps declining until the launch curve overtakes it.

11. Inflammation shows its first data

This was the first quarter in which Gilead's inflammation pipeline produced clinical data rather than deal announcements. Emvistegrast, a once-daily oral alpha-4-beta-7 inhibitor, met its primary endpoint in the Phase 2 SWIFT study in ulcerative colitis and moves to Phase 3 in 2027. Gilead agreed to acquire PepStar's oral IL-23 receptor inhibitor, HCXT-2001, for $1.275B upfront, a potential combination partner. Data for edecesertib, the IRAK4 inhibitor, in cutaneous lupus comes at ACR on November 8, and gamgertamig data in immune thrombocytopenia follows later this year.

"The data demonstrate the potential for best-in-class oral efficacy with a generally well-tolerated safety profile." — Dietmar Berger, Chief Medical Officer

Assessment: Thirteen clinical programs and one positive Phase 2 make inflammation a real third leg, but an early one. Phase 3 starts in 2027 put any revenue at the end of the decade, so this strengthens the long-term diversification pillar without changing the 2027 or 2028 numbers.

12. The M&A pause gets an asterisk, and the balance sheet rebuilds

In August the CFO said the company did not anticipate additional sizable M&A this year. PepStar at $1.275B upfront, plus a Vir Biotechnology research collaboration, adds about $1.4B of acquired IPR&D in the fourth quarter and lifts the full-year total to about $12.9B. The balance sheet meanwhile repaired quickly: cash rose to $6,437M from $3,179M in June on $5,035M of operating cash flow in the quarter, and stockholders' equity rose to $12,955M. The $1.1B one-year term loan, due April 2027, remains outstanding, and senior notes plus the term loan total $25,173M.

"Combined with our dividend, we have returned approximately 40% of our free cash flow to shareholders in the first 3 quarters of 2026." — Andrew Dickinson, Chief Financial Officer

Assessment: A $1.275B bolt-on is defensibly not "sizable" against the $11.5B already spent, and it fits the strategy. But the company did not revisit the August statement on the call, and investors who took it as a full stop for 2026 should register that the definition was flexible. The cash rebuild is the more important fact: the balance-sheet concern we raised in August has largely eased within one quarter.

Guidance & Outlook

For the third quarter running, the operating guide went up while the GAAP guide went down, and again for unrelated reasons. Everything tied to the business rose: product sales, HIV growth, ex-IPR&D operating income and illustrative EPS. Everything tied to deal accounting fell, because the PepStar and Vir upfronts add about $1.4B of acquired IPR&D in the fourth quarter, adding to the non-deductible charges that keep the reported tax rate in triple digits. The illustrative range is the right anchor, and it rose $0.25.

Implied fourth quarter: Year-to-date product sales of $22,862M against the $31.0B–$31.3B guide imply Q4 sales of $8.14B–$8.44B, up 3.0% to 6.8% on Q4 2025. The base business implies $8.09B–$8.39B, between 1.4% below and 2.3% above Q3. HIV at roughly 12% implies about $6.27B, flat sequentially and up about 8% year over year. Yeztugo implies about $298M, Veklury about $47M, and cell therapy roughly $366M–$403M.

Street at: Full-year total-revenue consensus sat near $30.77B before the print. The new product-sales midpoint of $31.15B is about 1.2% above it, and total revenue adds royalty income on top of product sales, so the like-for-like gap is somewhat wider. The pre-print full-year non-GAAP EPS consensus of about $(0.45) did not include the $1.4B of fourth-quarter IPR&D, which accounts for the gap to the $(1.20)–$(0.85) guide.

Guidance style: Third consecutive raise. HIV growth has gone from about 6% in February to 8%, then 9%–10%, and now about 12%, and the base-business guide is $1.65B above the initial midpoint. Gilead guides to a floor and raises into it. The Yeztugo guide has been held at about $1B since May, and on this quarter's run rate it is the most conservative number in the table.

Analyst Q&A Highlights

How the $1.5B Biktarvy impact splits between Medicare and other channels

The first substantive policy question asked how much of the $1.5B is the Medicare price itself and how much is spillover into Medicaid best price and 340B. Management confirmed the figure is a total net number and that Medicare is the larger part, but declined to give the split, citing how early it is.

Q: "Can you go over the moving pieces on the $1.5 billion IRA impact for Biktarvy pricing? How much of that is a net pricing impact for Medicare specifically versus the downstream impact on your, kind of, Medicaid best price and then the 340B impact."
— Akash Tewari, Jefferies

A: "So that is inclusive of the Medicare piece and all other spillovers to other channels in the U.S. And so to your question around, kind of, the split on that, we're not going to give all the details at this point in time as it's still very early. But having said that, it's primarily Medicare and then you have the spillover effect."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: The refusal matters more than it appears. The Medicare share is set by statute, but the spillover into Medicaid and 340B depends on how the new price interacts with best-price rules, and that is the part that could grow. A single net number is helpful for 2028 modelling and unhelpful for judging how much the company can mitigate.

What has to go right to grow HIV through the price cut

A follow-up asked whether the 2028 HIV growth commitment includes prevention, and what combination of market growth, new products and switching would offset the $1.5B. Management confirmed the commitment covers treatment and prevention together, and deferred specifics on mitigation.

Q: "Can you clarify, does your expectation to be able to grow the HIV franchise through that, does that include -- is that inclusive of PrEP? And then, I guess, I'm curious what, sort of, would need to happen in terms of overall market growth, new products and switches in order to be able to offset that $1.5 billion IRA impact to Biktarvy."
— Brian Abrahams, RBC Capital Markets

A: "And what we've said is, obviously, we will look to -- we have about a year or so, we will look at different opportunities to mitigate as much as possible the $1.5 billion, but that's in addition to the overall portfolio and of course, other strategies that we can look at. So more to come on that one."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Including prevention makes the commitment much more achievable, because the PrEP franchise is growing far faster than treatment. It also means the 2028 promise rests on Yeztugo and the weekly oral, not on the treatment pipeline. Saying "more to come" on mitigation is a fair answer fourteen months out, but it is not yet a plan.

Margins into 2027 and through the 2028 price cut

A margin question asked how the new deals' R&D and the 2028 Biktarvy price would affect operating margins. The CFO declined to quantify either year and argued instead that 2026 spending, ex the outperformance accruals, was on track with the original plan despite three acquisitions.

Q: "I was just wondering, Andy, if you can help us think about margin progression here into 2027. Obviously, you have done some business development deals. There's going to be some R&D spend behind those programs. And then also, as we think about the Biktarvy impact in '28, maybe just help us think high-level about impact to margins there, knowing it's a little early to give guidance, but just maybe directionally."
— Terence Flynn, Morgan Stanley

A: "So when you look at our updated guidance this year, we are right on track when you parse out both our R&D spend as well as our SG&A spend, right on track for the expenses that we were targeting at the beginning of the year in our initial guidance. And then we added in the additional compensation accruals and expenses tied to our significant outperformance this year as our expected bonus payments have gone up."
— Andrew Dickinson, Chief Financial Officer

Assessment: The 2026 argument is persuasive: the expense overrun is a bonus accrual, and the acquisitions were absorbed. But no 2028 margin number was given beyond an expectation of "very strong margins", and a $1.5B revenue reduction at near-100% incremental margin is a large operating-income hit to absorb in a single year. The EPS-growth commitment for 2028 implies the company expects to hold costs to make it.

What drove the quarter's realized price, and how much was inventory

The most useful exchange of the call asked why realized price strengthened and whether new-patient trends in treatment had changed. Management confirmed that the Q3 build was above normal across the whole HIV portfolio, and that price gains came from channel mix rather than list price.

Q: "I get the IRA impact longer term to HIV, but maybe can you talk about the trends you're seeing in 3Q? I wasn't sure the reason why you guys are now recognizing a stronger realized price. And then related, can you talk a little bit about if there's any discernible growth trends and just the number of new patients entering the HIV treatment market?"
— Geoffrey Meacham, Citigroup

A: "And we saw a little bit of a higher Q3 inventory than we usually see across all of our HIV portfolio, which is obviously something that we're conscious of and understand that, that might mean that the seasonal -- the typical seasonal Q4 inventory that plays out in Q4 usually might be a little softer than usual, but you'll still see a ramp-up, a buildup, and that's part of our guidance, of course. So there was an inventory play. There was also favorable pricing and the favorable pricing has to do with the channels."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Calling it "an inventory play" is as direct as management has been on the quality of HIV growth. The answer confirms our reading of the Genvoya and Odefsey sequential jumps, and it means channel mix and stocking, not volume, explain much of the gap between Biktarvy's 10% and Descovy's 49%. The new-patient half of the question got a share answer, first across naive, switch and restart patients, rather than a read on how many new patients are entering the market.

How the weekly oral PrEP launch will differ from Yeztugo's

A launch question asked what share of the prevention market a once-weekly oral could reach and how its ramp would compare with Yeztugo's. Management pointed to the large remaining daily-oral market and, more concretely, to the access already in place.

Q: "I just want to dig into the weekly oral PrEP launch as we head into next year. I guess, can you just help frame out what portion of the market you think this could appeal to? And maybe just compare and contrast a little bit how you're thinking about that launch relative to what we've seen with Yeztugo over the last year or so."
— Christopher Schott, JPMorgan

A: "And I would just add one more concept that's maybe a little bit different than a new launch because this is an extension based on Yeztugo in the weekly, we're going to be building off the access we already have on Yeztugo, specifically around the access we have in the pharmacy benefit space, which is about 70% or so."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer

Assessment: Launching into roughly 70% pharmacy-benefit access on day one is a real structural advantage, since access is what slowed Yeztugo's first quarters. This makes the weekly oral the most important single input to the 2028 HIV growth commitment.

Why the monthly oral treatment program is on clinical hold

A pipeline question asked for an update on GS-3107, the monthly oral treatment candidate placed on clinical hold. Management attributed the hold to unexpected metabolite effects seen with some prodrug compounds and said backup molecules are advancing in parallel.

Q: "On the HIV treatment pipeline, you had a disclosure around 3107 monthly oral with a clinical hold. Maybe you could just give us an update on that program and what is going on there?"
— Michael Yee, UBS

A: "For 3107, this is one of our prodrug compounds. And with some of the prodrug compounds, as you know, we saw metabolites that have an unexpected impact, and that is really the reason for the clinical hold at this point. We're working through that clinical hold."
— Dietmar Berger, Chief Medical Officer

Assessment: A class-level metabolite issue is more concerning than a molecule-specific one, because it could affect related prodrugs. Management gave no timeline for resolving the hold, so we treat the monthly oral as delayed indefinitely. It does not affect the weekly and twice-yearly programs that carry the 2028 plan.

The PALISADES partial hold and rapid manufacturing

A cell therapy question asked about the partial hold on the KITE-753 lymphoma trials and whether rapid manufacturing posed risk to other programs, including the autoimmune candidate KITE-363. Management said KITE-363 does not use rapid manufacturing and continues, and described the hold as a voluntary pause to investigate neurotoxicity.

Q: "I wonder if you could talk more about the PALISADES partial clinical hold and Whether taking that amongst some of the other competitive clinical holds, particularly with the fast manufacturing, how you're thinking about fast manufacturing and if there's any risk you see for KITE-363 in autoimmune disease as well, and, sort of, the timing for when we might better understand the risk for both of these programs."
— Daina Graybosch, Leerink Partners

A: "When you look at the partial clinical hold, we have made a decision to take a look at differences that we're seeing specifically with Grade 3 and Grade 4 ICANS in a small number of patients, and we have decided to take some time, pause and investigate that before we move forward. This is not -- there's no patient death. There's no Grade 5."
— Cindy Perettie, Executive Vice President, Kite

Assessment: A self-initiated pause with no deaths is the benign version of a clinical hold, and the separation of KITE-363's manufacturing process is a useful clarification. The timing half of the question was not answered.

Whether the two oral IBD drugs can practically be combined

An inflammation question pressed on whether the alpha-4-beta-7 inhibitor and the newly acquired oral IL-23 receptor peptide could be co-administered given their fasting requirements, which matters because combination use was part of the PepStar rationale. Management said the IL-23 program is too early to answer.

Q: "And my question is, if the alpha-4-beta-7 requires dosing as fasted and the IL-23, which is presumably a cyclic peptide, requires overnight fasting and perhaps waiting another 30 minutes post the dose, practically speaking, for a patient, how would the co-administration or the combo actually work?"
— Umer Raffat, Evercore ISI

A: "The IL-23 is very early. So we're still working on different types of formulations. So please stay tuned, and we'll inform you more about those details as we move along."
— Dietmar Berger, Chief Medical Officer

Assessment: A non-answer to a practical question. Management cited combination potential as part of the rationale for a $1.275B deal, and the most obvious practical obstacle to that combination has no solution yet. It does not undermine emvistegrast as a monotherapy, which is the asset that moves to Phase 3.

What They're NOT Saying

1. The size of the inventory build: Management acknowledged above-normal Q3 stocking across the HIV portfolio and guided a smaller Q4 build, but the release, the call and the Form 10-Q contain no dollar figure. One Street estimate puts it near half the revenue beat. For a quarter whose headline is 18% HIV growth, the size of the timing benefit is the most material number missing.
2. The Medicare-versus-spillover split of the $1.5B: Asked directly, management declined. The spillover is the mitigable and potentially growing part of the impact, so the split is what investors need to judge the 2028 risk.
3. How the $1.5B is offset: The commitment to grow HIV, total sales and EPS in 2028 came with no bridge, no product-level contributions and only "more to come" on mitigation.
4. Patent challenges to Descovy, Odefsey and Vemlidy: The 10-Q discloses Section 505(b)(2) applications with paragraph IV certifications against Descovy and Odefsey patents from Cipla, and against all Orange Book patents for Descovy and Vemlidy from Zydus, with Gilead suing in each case. Descovy is now a $1B-a-quarter product, and none of this came up on the call.
5. Four fewer clinical programs: The chief medical officer cited 53 ongoing clinical programs in August and 49 this quarter. Neither the call, the release nor the 10-Q explains which programs left the count or why, in a quarter that also added new trials and an acquisition.
6. The legal costs inside SG&A: The release attributes part of the SG&A increase to "higher expenses related to legal matters." The 10-Q separately discloses an October 2026 settlement of the Texas qui tam litigation in which the state attorney general had intervened, with no amount given. Neither document sizes the legal expense or says which matters drove it.
7. The August M&A statement: Three months after saying it did not anticipate additional sizable M&A this year, Gilead agreed to a $1.275B asset purchase. The call did not address whether the earlier statement still holds.

Market Reaction

• Pre-print setup: Gilead closed at a record $165.61 on October 29, the top of its 52-week closing range of $117.88–$165.61, after rising 4.0% in the regular session ahead of the release. The stock entered the print up 34.9% year to date against 12.8% for the S&P 500, up 39.8% over twelve months and up 9.5% over thirty days. It had risen 25.7% from the $131.76 close on August 5, the reaction session our August note covered.
• After-hours move: Shares rose roughly 2% to 4% in extended trading on October 29.
• Reaction session (Oct 30): The stock gapped up 2.8% to open at $170.25, traded between $169.00 and $175.65, and closed at $170.68, up 3.1% or $5.07. The S&P 500 fell 1.8% the same session.
• Volume: 11.4 million shares against a 30-day average of 6.1 million, roughly 1.9 times normal.
• Peer reaction: Large-cap biopharma rallied on a down day for the market. Amgen rose 1.1%, Vertex 3.5%, AbbVie 1.4%, Merck 2.2%, Bristol Myers Squibb 1.8% and GSK 1.7%, an average of about 2.0%, while the iShares Biotechnology ETF slipped 0.1%.

A beat on a defensive-rotation day

The 3.1% gain overstates the stock-specific reaction. On a session when the S&P 500 fell 1.8%, large-cap pharma and biotech rose about 2% as a group, so Gilead's excess over its peers was roughly one point. For the best base-business quarter in a decade and a $900M guide raise, a one-point excess return is muted. The two-day move from the October 28 close was 7.2%, but the first 4.0% came before the release, in a session when Merck also rose 3.8%.

The fade from $175.65

The shape of the session told more than the close. The stock traded as high as $175.65, up 6.1%, and gave back about half of that to close in the lower part of its range. The likely reason is the rest of the evening's disclosure. The 2026 numbers were unambiguously good, but the release said CMS had set Biktarvy's Medicare price, the call put a $1.5B 2028 cost on it, and the call also confirmed that part of Q3 was inventory. Buyers paid for the headline at the open, and the afternoon priced the caveats.

What the market is now paying for

At $170.68 the stock trades at 19.1x the midpoint of management's illustrative 2026 range, against 15.2x after our August note and 18.0x when we initiated at Hold in February, all on the same 2026 earnings basis. The illustrative midpoint rose 2.9% since August; the stock rose 29.5%. Nearly all of the move since August is multiple expansion, which means the market has already credited the HIV acceleration, the PrEP leadership and the 2028 growth commitment.

Street Perspective

Debate: Is the HIV acceleration repeatable, or was Q3 borrowed from Q4?

Bull view: HIV growth was raised to about 12% for the year, the third raise in three quarters, on prevention volume that nearly doubled and a record 53% Biktarvy treatment share. Even after the inventory unwind, the franchise is growing at roughly twice the rate assumed in February, and several desks see underlying momentum and durability improving rather than peaking.

Bear view: One Street estimate puts roughly half of the revenue beat in inventory, the filing credits Descovy's growth primarily to price and stocking, and the guide itself implies HIV growth falling to about 8% in Q4. Price from channel mix is finite, and the treatment market has still not returned to its normal 2%–3% growth.

Our take: The bulls are right about prevention and the bears are right about Q3. Underlying HIV growth is probably 12% to 13%, which is excellent, but the fourth quarter will print well below Q3, and the stock is priced as if the headline rate holds.

Debate: Does the 2028 Biktarvy price cap the multiple?

Bull view: The $1.5B is about 5% of this year's product sales, it is two years out, and management has committed to growing HIV revenue, total sales and EPS through it on the strength of the long-acting portfolio. A known, sized and bounded headwind is better than an open-ended policy overhang.

Bear view: Biktarvy alone is roughly half of company sales, and the first IRA price sets a precedent for future selection rounds and channel spillovers. Some on the Street now question how long HIV franchise growth can persist under competition and price setting, and generic challengers have filed against Descovy and Vemlidy.

Our take: The bull side has the better of the 2028 argument, because management bounded the risk with a growth commitment. But the HIV annuity now has a dated step-down that it did not have when we upgraded, and that justifies a lower multiple than an untouched annuity to 2036, not a higher one.

Debate: Is 19x the new normal for Gilead?

Bull view: Post-print price targets were raised across the Street, to a range of roughly $175 to $200 with averages in the mid-to-high $180s, about 8% to 10% above the reaction close. A company growing its base business at double digits with a 50% operating margin, a de-risked prevention franchise and an emerging inflammation pipeline deserves a premium to large-cap pharma.

Bear view: The multiple went from 15x to 19x in three months on a 2.9% increase in the earnings estimate. Fourth-quarter growth will decelerate sharply, 2027 absorbs an inventory reversal and higher operating costs, and 2028 absorbs the Biktarvy cut. Nineteen times is a full price for that path.

Our take: The bear case is right on valuation even though the bull case is right on the business. The stock now trades above our fair value range, and the remaining upside to the Street's targets assumes a further re-rating we do not see a catalyst for before February's 2027 guide.

Model Update Needed

Valuation impact: In May we set fair value in the high-$150s to low-$160s. On the then-midpoint of $8.65 of illustrative 2026 EPS, that range implies roughly 18.2x to 18.8x; the multiple is our back-solve, not a figure the May note stated. Re-deriving on the new $8.925 midpoint at the same multiples gives about $162–$168. We do not raise the multiple: the Biktarvy price is a new, dated negative for the HIV annuity, and the inventory build means Q3 overstates the run rate. At $170.68 the stock sits above that range, with a 1.9% dividend yield. Raised Street targets in the mid-to-high $180s imply roughly 8% to 10% upside, but they need the multiple to expand further from 19x, which we are not prepared to underwrite before the 2027 guide.

Thesis Scorecard Post-Earnings

August checkpoints graded: The BIC/LEN decision came in August as an approval, and Bixlenvo launched (met). Yeztugo reached $305M, the roughly $300M a quarter the guide needed (met). The HIV treatment market has not yet returned to 2%–3% growth, though management reports stabilization (not yet met). SG&A did not retreat to a mid-single-digit pace; the guide moved to high single digits on bonus accruals (not met, with a benign explanation).

Overall: The thesis strengthened on operations and weakened on price. Every bull pillar was confirmed or held, the conversion problem behind last quarter's held conviction is resolved, and the balance sheet repaired faster than we expected. Against that, the policy risk materialized as a sized 2028 liability, and the valuation risk that anchored our February Hold has returned at a higher multiple than it was then.

Action: Downgrade to Hold from Outperform, conviction to 6 from 7. The upgrade thesis was a de-rated stock with an accelerating base business, and the stock has re-rated 30% since then against a market up 2.4%. We would return to Outperform on a pullback toward $150, about 17x the illustrative midpoint, with the operating trajectory intact, or if February's 2027 guidance implies earnings growth that lifts fair value clearly above the price. We would turn more cautious if fourth-quarter HIV sales decline sequentially, which would mean the Q3 build was larger than management has described.